(EP3092213) Allosteric hemoglobin modifiers with nitric oxide releasing moiety 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(EP3092213) Allosteric hemoglobin modifiers with nitric oxide releasing moiety
公开号/公开日
EP3092213EP3092213EP3092213 / 2019-10-232017-08-232016-11-16
申请号/申请日
EP14874450 / 2014-12-22
发明人
SAFO MARTIN KDANSO-DANQUAH RICHMONDGHATGE MOHINIVENITZ JURGENMANGINO MARTINWARD KEVIN R;
申请人
VIRGINIA COMMONWEALTH UNIVERSITY;
主分类号
IPC分类号
A61K-031/166 A61K-031/216 A61K-031/40 A61K-031/655 A61K-033/00 A61K-045/06 A61P-009/00 A61P-011/00 A61P-025/00 A61P-029/00 A61P-033/06 A61P-035/00 A61P-037/00 A61P-043/00 C07C-233/07 C07C-235/38 C07C-245/24
摘要
(EP3092213) Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
(EP3092213) Nony ([FR]) Reg. Nb: 101303589
代理机构
;
优先权号
2013US-61921204 2014WO-US71888
主权利要求
(EP3092213) 1. A compound having the general formula:wherein   R1 and R2 are the same or different and are CH3, Cl, H, OCH3, or 5-carbon cyclic incorporating both R1 and R2;   R3 is H, OH, COOH, or OC2H5;   R4 and R5 are the same or different and are H, CH3, cyclic incorporating both R4 and R5 and containing CH3 substituents, OCH3, C2H5, phenyl, or unsubstituted phenyl; and   R6 is a NO containing moiety. 2. The compound of claim 1 wherein R6 is selected from the group consisting of: 3. The compound of claim 1 having the formula: 4. A composition, comprising:   one or more compounds as specified in claim 1; and   a carrier. 5. The composition of claim 4 wherein said carrier is a liquid, and wherein said one or more compounds are dissolved or distributed in said liquid, in particular said liquid is an aqueous liquid or an oil; or said carrier is a solid; or said carrier is a gas, in particular said gas is air. 6. Compounds having the general formula:wherein   R1 and R2 are the same or different and are CH3, Cl, H, OCH3, or 5-carbon cyclic incorporating both R1 and R2;   R3 is H, OH, COOH, or OC2H5;   R4 and R5 are the same or different and are H, CH3, cyclic incorporating both R4 and R5 containing CH3 substituents, OCH3, C2H5, phenyl, or unsubstituted phenyl; and   R6 is a NO containing moiety,   for use for treating inflammatory diseases, cardiovascular diseases, septic, hemorrhagic and traumatic shock, stroke, ischemic-related diseases, cerebral traumas, angina, Alzheimer's, depression, Schizophrenia, severe infection, cardiac arrest, cardiogenic shock, severe burns and wounds, transplant surgeries, Crohn's disease, radiation poisoning, traumatic brain injury, myocardial infarction, vasoocclusive crisis, severe respiratory distress from asthma, chronic obstructive pulmonary diseases, acute respiratory distress syndrome, pulmonary hypertension, preeclampsia, eclampsia, malaria, influenza, organ transplant, coronary heart disease, cerebrovascular disease, hypertension, arthritis, cancer, and diabetes. 7. Compound for use according to claim 6, wherein R6 is selected from the group consisting of: 8. The compound for use according to claim 6, wherein the compound has the formula: 9. Compound having the general formula:wherein   R1 and R2 are the same or different and are CH3, Cl, H, OCH3, or 5-carbon cyclic incorporating both R1 and R2;   R3 is H, OH, COOH, or OC2H5;   R4 and R5 are the same or different and are H, CH3, cyclic incorporating both R4 and R5 containing CH3 substituents, OCH3, C2H5, phenyl, or unsubstituted phenyl; and   R6 is a NO containing moiety; and at least one hemoglobin based oxygen carrier (HBOC) for use for treating inflammatory diseases, cardiovascular diseases, septic, hemorrhagic and traumatic shock, stroke, ischemic-related diseases, cerebral traumas, angina, Alzheimer's, depression, Schizophrenia, severe infection, cardiac arrest, cardiogenic shock, severe burns and wounds, transplant surgeries, Crohn's disease, radiation poisoning, traumatic brain injury, myocardial infarction, vasoocclusive crisis, severe respiratory distress from asthma, chronic obstructive pulmonary diseases, acute respiratory distress syndrome, pulmonary hypertension, preeclampsia, eclampsia, malaria, influenza, organ transplant, coronary heart disease, cerebrovascular disease, hypertension, arthritis, cancer, and diabetes. 10. Compound for use according to claim 9, wherein R6 is selected from the group consisting of: 11. Compound for use according to claim 9, wherein the compound has the formula: 12.   i) An allosteric effector of Hb having the general formula:wherein    R1 and R2 are the same or different and are CH3, Cl, H, OCH3, or 5-carbon cyclic incorporating both R1 and R2;    R3 is H, OH, COOH, or OC2H5;    R4 and R5 are the same or different and are H, CH3, cyclic incorporating both R4 and R5 containing CH3 substituents, OCH3, C2H5, phenyl, or unsubstituted phenyl; and    R6 is a NO containing moiety; and   ii) one or both of a hemoglobin based oxygen carrier (HBOC) and a perfluorocarbon (PFC), for use for treating gas poisoning in a patient. 13. (i) and (ii) as defined for use according to claim 12, wherein said gas is selected from the group consisting of CO, H2S, and NO2.
法律状态
GRANTED
专利类型码
B1A4A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部